Clinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
NCT03992846 is registered in ClinicalTrials.gov with Kissei Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 13, 2019
- Completion date
- April 1, 2022
- Enrollment
- 486 (actual)
- Sites
- 71
Conditions
As the registry lists them; a condition with its own page is linked.